Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study.

about

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

P2860

Q52714397-987B854F-FA20-4F94-8D3E-BB69B178C6C7

P2860

Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study.

Item

http://www.wikidata.org/entity/Q38936142

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Hematological approaches to mu ...... ists. A cross-sectional study.

@en

type

Item

label

Hematological approaches to mu ...... ists. A cross-sectional study.

@en

prefLabel

Hematological approaches to mu ...... ists. A cross-sectional study.

@en

P1476

Hematological approaches to mu ...... gists. A cross-sectional study

@en

P2093

Breno Moreno de Gusmão

http://www.w3.org/2001/XMLSchema#string

Lucila Nassif Kerbauy

http://www.w3.org/2001/XMLSchema#string

Nelson Hamerschlak

http://www.w3.org/2001/XMLSchema#string

Simrit Parmar

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Lenalidomide after stem-cell transplantation for multiple myeloma

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Epidemiology of multiple myeloma.

Frontline therapy of multiple myeloma.

Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

P304

335-341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/1516-3180.2015.0223030416

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

José Mauro Kutner

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27557143

http://www.w3.org/2001/XMLSchema#string

Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study.

about

P2860

P2860

Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698